Key result
Continuing 100 mg of ASA during transurethral surgery resulted in no significant differences in postoperative haemorrhage or operative revision compared to discontinuing ASA.
Why the study?
Does continuation of acetylsalicylic acid 100 mg increase bleeding complications in patients undergoing transurethral interventions?
Population
346 patients undergoing transurethral resection of prostate or bladder tumours with low or medium cardio- or…
Comparison
Continuation of acetylsalicylic acid 100 mg… vs Discontinuation of acetylsalicylic acid…
Design
Cohort
Follow-up
until the day of discharge
Authors
Loading...
May support ASA continuation without excess revision risk; leaves open need for randomized confirmation before practice change.
Cohort (n=346)
Does continuation of acetylsalicylic acid 100 mg increase bleeding complications in patients undergoing transurethral interventions?
Continuation of 100 mg ASA during transurethral interventions increases postoperative bleeding in TURP but does not significantly increase the need for surgical revision, suggesting it is a feasible approach for patients with verified indications for platelet inhibition.
Wenders et al. (2012) conducted a cohort in Transurethral interventions (TURP/TURB) (n=346). Acetylsalicylic acid (ASA) vs. Discontinuation of ASA was evaluated on Postoperative haemorrhage, operative revision, length of stay, and time until catheter removal. Continuing 100 mg of ASA during transurethral surgery resulted in no significant differences in postoperative haemorrhage or operative revision compared to discontinuing ASA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: